IDEAYA Updates Darovasertib Phase 2/3 Trial Timeline
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
Regulatory Submission
Advertisement
NanoViricides Files FDA Orphan Drug Bid for NV-387
Shelton, Connecticut — February 10, 2026: NanoViricides, Inc., a clinical-stage antiviral nanomedicine company, announced the filing of an Orphan...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
